...that states Genta has received financing that will allow the company to finish the Agenda Clinical Trial, end to end, as well as continue Tesetaxel exploration, with no dilution...my money will certainly be back in this security.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.